Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Finerenone is a non-steroidal mineralocorticoid receptor antagonist (IC50 = 18 nM).1 It is selective for the mineralocorticoid receptor over glucocorticoid, progesterone, and androgen receptors (IC50s = >10,000 nM for all), as well as L-type calcium channels (IC50 = >10,000 nM). Finerenone (3 mg/kg) reduces renal vasculopathy, fibrosis, and tubular degeneration, as well as cardiac fibrosis, in a rat model of hypertension-induced end-organ damage.2 It also increases exercise capacity and prevents diastolic dysfunction in ovariectomized mice.3
WARNING This product is not for human or veterinary use.
1. Steroidal and novel non-
2. Effects of finerenone combined with empagliflozin in a model of hypertension-
3. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail. 8(3), 1933-1943 (2021).